29 reports of this reaction
2.9% of all SODIUM MONOFLUOROPHOSPHATE reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for SODIUM MONOFLUOROPHOSPHATE, manufactured by Haleon US Holdings LLC. There are 29 FDA adverse event reports linking SODIUM MONOFLUOROPHOSPHATE to DYSPNOEA. This represents approximately 2.9% of all 998 adverse event reports for this drug.
Patients taking SODIUM MONOFLUOROPHOSPHATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for SODIUM MONOFLUOROPHOSPHATE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for SODIUM MONOFLUOROPHOSPHATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 29 FDA reports for SODIUM MONOFLUOROPHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.9% of all adverse event reports for SODIUM MONOFLUOROPHOSPHATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking SODIUM MONOFLUOROPHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.